Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.

The highly pathogenic simian immunodeficiency virus/HIV type 1 (SHIV) chimeric virus SHIV(DH12R) induces a systemic depletion of CD4(+) T lymphocytes in rhesus monkeys during the initial 3-4 weeks of infection. Nonetheless, high levels of viral RNA production continue unabated for an additional 2-5 months. In situ hybridization and immunohistochemical analyses revealed that tissue macrophage in the lymph nodes, spleen, gastrointestinal tract, liver, and kidney sustain high plasma virus loads in the absence of CD4(+) T cells. Quantitative confocal immunofluorescence analysis indicated that greater than 95% of the virus-producing cells in these tissues are macrophage and less than 2% are T lymphocytes. Interestingly, the administration of a potent reverse transcriptase inhibitor blocked virus production during the early T cell phase but not during the later macrophage phase of the SHIV(DH12R) infection. When interpreted in the context of HIV-1 infections, these results implicate tissue macrophage as an important reservoir of virus in vivo. They become infected during the acute infection, gradually increase in number over time, and can be a major contributor to total body virus burden during the symptomatic phase of the human infection.

[1]  J. Metcalf,et al.  HIV-1 replication in patients with undetectable plasma virus receiving HAART , 1999, The Lancet.

[2]  W. Wachsman,et al.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection , 1992, Neurology.

[3]  D. Richman,et al.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. , 1999, Science.

[4]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[5]  S. Broder,et al.  Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'- dideoxynucleosides , 1988, The Journal of experimental medicine.

[6]  D. Montefiori,et al.  A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3 , 1997, Journal of virology.

[7]  Anthony S. Fauci,et al.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy , 2000, Nature Medicine.

[8]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[9]  H. Gendelman,et al.  Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. , 1986, Science.

[10]  R. Grant,et al.  Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine , 1995, Science.

[11]  S. Aquaro,et al.  Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. , 1998, The Journal of infectious diseases.

[12]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[13]  P. Johnson,et al.  Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication , 1995, Journal of virology.

[14]  D. Markovitz,et al.  The role of mononuclear phagocytes in HTLV-III/LAV infection. , 1986, Science.

[15]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[16]  D. Dieterich,et al.  Identification and quantitation of HIV‐1 in the liver of patients with AIDS , 1992, AIDS.

[17]  J. Sodroski,et al.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys , 1996, Journal of virology.

[18]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[19]  C. Sumaya,et al.  Cerebrospinal fluid abnormalities in patients without AIDS who are seropositive for the human immunodeficiency virus. , 1988, The Journal of infectious diseases.

[20]  J. Balzarini,et al.  Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes , 1997, Journal of leukocyte biology.

[21]  D. Ho,et al.  Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. , 2000, The Journal of clinical investigation.

[22]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[23]  P. Simmonds,et al.  Redistribution of HIV outside the lymphoid system with onset of AIDS , 1994, The Lancet.

[24]  P. Fultz,et al.  Identification and biologic characterization of an acutely lethal variant of simian immunodeficiency virus from sooty mangabeys (SIV/SMM). , 1989, AIDS research and human retroviruses.

[25]  A. Fauci,et al.  CCR5 Signal Transduction in Macrophages by Human Immunodeficiency Virus and Simian Immunodeficiency Virus Envelopes , 2000, Journal of Virology.

[26]  K. E. Follis,et al.  Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. , 1997, AIDS research and human retroviruses.

[27]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. McClure,et al.  Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques , 1996, Journal of virology.

[29]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[30]  B. Rosenwirth,et al.  In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages , 1994, Journal of leukocyte biology.

[31]  R. Lempicki,et al.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Sidtis,et al.  Early HIV‐1 infection and the AIDS dementia complex , 1990, Neurology.

[33]  R. Willey,et al.  Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope , 1994, Journal of virology.

[34]  C. Wiley,et al.  Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Gendelman,et al.  Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease. , 1990, AIDS research and human retroviruses.

[36]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[37]  D. Dimitrov,et al.  Short- and Long-Term Clinical Outcomes in Rhesus Monkeys Inoculated with a Highly Pathogenic Chimeric Simian/Human Immunodeficiency Virus , 2000, Journal of Virology.

[38]  M. Martin,et al.  Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. , 1997, The Journal of infectious diseases.

[39]  J. Lifson,et al.  Effectiveness of Postinoculation (R)-9-(2-Phosphonylmethoxypropyl)Adenine Treatment for Prevention of Persistent Simian Immunodeficiency Virus SIVmne Infection Depends Critically on Timing of Initiation and Duration of Treatment , 1998, Journal of Virology.

[40]  M. Martin,et al.  Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R Blumenthal,et al.  Quantitation of human immunodeficiency virus type 1 infection kinetics , 1993, Journal of virology.

[42]  C. Fox,et al.  Macrophages as a source of HIV during opportunistic infections. , 1997, Science.

[43]  T. Elbeik,et al.  Comparative assessment of antiretrovirals in human monocyte‐macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus , 1989, Journal of medical virology.

[44]  S. Aquaro,et al.  HIV infection in macrophage: role of long-lived cells and related therapeutical strategies. , 1997, Journal of biological regulators and homeostatic agents.